Active	Status	Sponsor type	Region	Phase	Filter
13 Active 0 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shibata, Yoshisato
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]	Active, not recruiting	2	216	Europe, Japan, US, RoW	LY3819469, Placebo	Eli Lilly and Company	Lipoprotein Disorder	10/23	10/24
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Completed	2	233	Europe, Japan, US, RoW	LY3473329, Placebo	Eli Lilly and Company	Lipoprotein Disorder	03/24	03/24
JNIR, NCT02828917: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial	Completed	N/A	104	Japan	MedJ-01 Ridaforolimus Eluting Coronary Stent System	Medinol Ltd.	de Novo or Restenosis Lesions	06/18	08/22
Nishihira, Kensaku
REASSURE-NIRS, NCT04864171: Registry	Recruiting	N/A	2000	Japan	near-infrared spectroscopy	National Cerebral and Cardiovascular Center	Lipid-Rich Atherosclerosis of Coronary Artery	12/24	03/25
Haraguchi, Mikiko
NCT05326230: A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)	Recruiting	N/A	154	Japan	Paradise™ (PRDS-001) Renal Denervation Ultrasound System, Renal Angiogram/Renal Denervation, Renal Angiogram	Otsuka Medical Devices Co., Ltd. Japan	Hypertension, Vascular Diseases, Cardiovascular Diseases	12/25	12/29
NCT05759819: Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients With Peripheral Arterial Occlusive Disease	Active, not recruiting	N/A	24	Japan	Standard stenting	Otsuka Medical Devices Co., Ltd. Japan	Peripheral Arterial Disease	12/24	12/26
Kirschner, Robert J
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Overweight and Obesity	02/29	02/29
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Completed	2	233	Europe, Japan, US, RoW	LY3473329, Placebo	Eli Lilly and Company	Lipoprotein Disorder	03/24	03/24
NCT05514548: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Active, not recruiting	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	07/24	09/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Recruiting	2	456	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	11/25	01/26